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Abstract
Background: Treatment of recurrent gynecologic cancer is a challenging issue. Aim of the study was to investigate
clinical features and outcomes of patients with recurrent gynecologic malignancies who underwent resection
including IOERT (intraoperative electron radiation therapy) with regard to clinical outcome and potential predictive
factors or subgroups that benefit most from this radical treatment regime.
Methods: A total of 36 patients with recurrent gynecologic malignancies (cervical (n= 18), endometrial (n = 12) or vulvar
cancer (n = 6)) were retrospectively identified through hospital databases in accordance with institutional ethical policies.
Patient characteristics and outcomes were assessed. Survival data was analyzed using the Kaplan-Meier-method and log-
rank-test, categorical variables were analyzed with chi-square-method.
Results: For the entire cohort 1-/2-/5-year Overall Survival (OS) was 65.3 %/36.2 %/21.7 %. Patients with endometrial,
cervical, and vulvar carcinoma had a 1-/2-/5-year OS of 83.3 %/62.5 %/50 %, 44.5 %/25.4 %/6.4 %, and 83.3 %/16.7 %/
16.7 %, respectively. Patients with endometrial carcinoma showed a significantly better OS (p = 0.038).
1-/2-/5-year Local Progression-free Survival (LPFS) for the entire cohort was 44.1 %/28 %/21 % with 76.2 %/61 %/40.6 %
for endometrial, 17.2 %/0 %/0 % for cervical, and 40 %/20 %/20 % for vulvar cancer, respectively. Patients with
endometrial cancer showed a significantly (p = 0.017) and older patients a trend (p = 0.059) for a better LPFS.
1-/2-/5-year Distant Progression-free Survival (DPFS) for the entire cohort was 53.1 %/46.5 %/38.7 % with
74.1 %/74.1 %/74.1 % for endometrial, 36.7 %/36.7 %/0 % for cervical, and 60 %/30 %/30 % for vulvar cancer,
respectively. There was a significantly better DPFS for older patients (p = 0.015) and a trend for a better DPFS
for patients with endometrial carcinoma (p = 0.075).
Conclusion: The radical procedure of resection combined with IOERT seems to be a valid curative treatment
option for patients with recurrent endometrial carcinoma with 5-year survival rates of 50 %. For patients with
cervical or vulvar cancer this treatment should be considered a rather palliative one and must be weighted
carefully against other treatment options like chemotherapy, targeted therapies or new highly conformal
radiotherapy techniques.
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Background
Every year almost 95,000 women are diagnosed with a
gynecologic malignancy [1]. Fortunately, the majority
can be cured. Around 30 % will experience cancer recur-
rence, often with a dismal prognosis. Endometrial carcin-
oma represents the most common gynecologic malignancy.
Patients with endometrial carcinoma generally have a good
prognosis as most women are diagnosed in an early stage
and can by cured by surgery. 5-year survival rates of
80–90 % have been reported [2–4]. Risk of local
recurrence – defined as isolated vaginal recurrence -
can even be lowered by the additional use of adjuvant
pelvic radiotherapy as shown in the PORTEC-trial
(incidence of vaginal recurrence of 2 % in the radio-
therapy group versus 8 % in the control group) [4–7].
Nevertheless, the prognosis for women with advanced
stage disease or high-risk histologies is poor with 5-year
survival rates of 57 % for Stage III and 19 % for Stage IV
tumors [4, 8]. All in all, 15 % of all women with endomet-
rial cancer experience recurrence, with more than 50 %
occurring within 2 years of primary treatment [4].
The incidence of cervical carcinoma has decreased in
the Western countries over the last years but still remains
a significant public health problem worldwide. The risk of
recurrence after primary treatment depends on the tumor
stage as well as on other risk factors like tumor size, lym-
phonodal status, deep stromal invasion or parametrial and
surgical margin involvement [9, 10]. Most recurrences of
cervical carcinoma occur within 18–24 months from the
time of diagnosis [11, 12], whereas 70 % of the recurrences
are pelvic ones. The 5-year survival rate after recurrence
in high-risk patients is less than 10 % [13]. The site of
relapse is a significant prognostic factor [13] with
worse results for patients with pelvic wall recurrences
[12, 14–17].
Vulvar cancer represents 5 % of all gynecologic malig-
nancies [8, 18]. Inguinal and femoral lymphatic node
involvement is the most important prognostic factor for
survival with a 5-year survival rate of 70–93 % for
patients without lymph node involvement and only
25–41 % for those with positive lymph nodes [19, 20].
Local or distant recurrences are generally difficult to
treat and the 5-year survival rate is less than 5 % [21].
In general, defining the treatment of choice for recur-
rent gynecologic cancer is a challenging issue. Many
different factors must be taken into consideration such
as the type of primary therapy, the site of recurrence,
the disease-free interval, the patient’s symptoms and per-
formance status and the degree to which any given treat-
ment might be beneficial [12].
Pelvic exenteration may be considered in cases of recur-
rent or advanced-stage tumors with bladder and/or rectum
infiltration neither extended to the pelvic side walls nor
showing any distant metastases. High overall morbidity
rates of about 70 % are still reported [12, 22, 23]. The post-
operative mortality has decreased over time with nowadays
0–5.3 % [24, 25]. However, 5-year survival rates of
20–73 % after pelvic exenteration have been reported
depending on disease situation and stage [12].
If resection or pelvic exenteration alone is not likely to
produce satisfactory results, IOERT should be taken into
consideration to increase the chance of local control.
Improved outcome especially in case of close or positive
margins has been reported for other pelvic diseases like
locally recurrent rectal cancer previously [26]. The rec-
ommended doses depend on the exposure due to prior
radiation treatment and the extent of residual tumor dis-
ease after resection, ranging from 10 to 20 Gy [12].
However, due to the rarity of the mentioned disease situa-
tions and the restricted availability of IOERT only scarce
data on efficacy and toxicity of the combined treatment
approach exists. We therefore analyzed our patients with
recurrent gynecologic malignancies who underwent resec-
tion including IOERT at University Hospital Heidelberg
between 2002 and 2014 with regard to clinical outcome
and potential predictive factors or subgroups that benefit
most from this radical treatment regime.
Patients and methods
There were 36 patients with recurrent gynecologic ma-
lignancies including cervical (=18), endometrial (n = 12),
and vulvar cancer (n = 6) between 2002 and 2014 who
had resection combined with IOERT at University
Hospital Heidelberg.
Computerized database was used to perform a review
of medical records in order to abstract patient and treat-
ment characteristics. All data were collected retrospect-
ively and in accordance with institutional ethical policies.
The following clinical data were collected: age, tumor
type, date of first diagnosis, prior treatment, time to recur-
rence, pattern of recurrence including organ infiltration,
lymphonodal status, existence of a lymphangiosis carcino-
matosa, extent of resection, resection margins, perform-
ance of IOERT including dose, energy and cone size,
onset and localization of distant metastases and further
local recurrences, date and cause of death, toxicities and
treatment associated complications.
There were no restrictions to the type of prior treat-
ment (Table 1). In the cervical cancer group 17 patients
had a tumor resection before. 5 patients had an EBRT
(median dose 52.2 Gy, range 45–55.6 Gy), 8 patients had
concurrent chemotherapy with cisplatin or cisplatin/5-
fluorouracil (median dose 50.4 Gy, range 50.4–58.5 Gy), 2
patients had an additional brachytherapy as a boost (me-
dian dose 30 Gy, range 20–40 Gy) and another 2 patients
had brachytherapy in a separate time frame from EBRT
(15 Gy for one patient, dose information n.a. for the other
patient). 4 patients didn’t have any radiotherapy before
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resection + IOERT. Two patients had chemotherapy alone
in the course of their treatments. All patients with endo-
metrial cancer had a hysterectomy before. 7 patients re-
ceived vaginal brachytherapy (median dose 21 Gy, range
15–30 Gy). One patient had additional EBRT (50.4 Gy
with 20 Gy brachytherapy as a boost, and later another
EBRT with 50 Gy) and another patient had EBRT alone
(50.4 Gy). Two patients had chemotherapy alone in the
course of their treatments. All patients with vulvar cancer
had a tumor resection, 5 had an additional EBRT (median
dose 50.4 Gy, range 50–61.2 Gy), one patient had concur-
rent EBRT and chemotherapy with cisplatin/5-fluorouracil
(dose information n.a.).
Patients with recurrent gynecologic cancer were gener-
ally discussed in an interdisciplinary setting. If there
were no other curative options left and patients were eli-
gible for resection and IOERT with expected reasonable
morbidity and toxicity this therapeutic option was
offered to the patients. The extent of resection was
depending on the pattern of tumor recurrence. All pa-
tients received IOERT. The operations were performed
by gynecologic, urologic, visceral or even plastic and vas-
cular surgeons from the University Hospital Heidelberg.
All recurrences were histologically confirmed. The tech-
nique of IOERT used at our institution has been de-
scribed previously [26]. Briefly, IOERT was performed in
a dedicated operation room with an integrated linear ac-
celerator capable of delivering 6–18 MeV electrons. The
target area was defined in correspondence with the sur-
geon and usually included the high risk area for positive
margins with a safety margin of 1 cm. Uninvolved radio-
sensitive tissues (for example major nerves, ureters and
bowel structures) were displaced or protected by lead
shields whenever possible. The median IOERT dose was
15 Gy (range 10–18 Gy) with a median energy of 8 MeV
(range 6–15 MeV), prescribed to the 90 %-isodose.
Table 1 Prior treatment regimens and dose specifications by tumor type
Number Median dose Dose range IOERT IOERT
median dose dose range
A. Cervical cancer
Cervical cancer (n = 18)
Resection 17 – – – –
EBRT alone 5 52.5 45–55.6 15 12–15
EBRT + CHT 8 50.4 50.4–58.5 15 10–18
EBRT + Brachytherapy 4 50 + 20 36–50.4 + 15–40 15 12–15
Brachytherapy alone 0 – – – –
CHT alone 2 – – – –
No prior radiation 4 – – 12 10–15
B. Endometrial cancer
Endometrial cancer (n = 12)
Resection 12 – – – –
EBRT alone 1 50.4 – 15 15
EBRT + CHT 0 – – – –
EBRT + Brachytherapy 1 50.4 + 20; 50 – 10 10
Brachytherapy alone 7 21 15–30 15 10–15
CHT alone 2 – – – –
No prior radiation 3 – – 15 10–15
C. Vulvar cancer
Vulvar cancer (n = 6)
Resection 6 – – – –
EBRT alone 5 50.4 50–61.2 15 12–15
EBRT + CHT 1 n.a. n.a. 15 15
EBRT + Brachytherapy 0 – – – –
Brachytherapy alone 0 – – – –
CHT alone 0 – – – –
No prior radiation 0 – – – –
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IOERT dose was usually restricted to 10–12 Gy, if major
nerves had to be included into the radiation field. De-
tailed information about the IOERT doses depending on
tumor type and previous treatment regimens are listed
in Table 1.
Further treatment after resection combined with
IOERT was very variable, depending on the clinical char-
acteristics of each patient. One cervical cancer patient
without any previous radiation therapy received adjuvant
radiochemotherapy with a dose of 45 Gy combined with
cisplatin 30 mg/m2 body surface weekly (IOERT dose:
12 Gy). Another cervical cancer patient stopped adju-
vant EBRT after 5.4 Gy. One vulvar cancer patient with
prior EBRT with 56 Gy had adjuvant radiochemotherapy
with 45 Gy and cisplatin 40 mg/m2 body surface weekly
(IOERT dose: 15 Gy). Two patients with endometrial
cancer had adjuvant EBRT. One patient without any pre-
vious radiation received 41.4 Gy (IOERT dose: 10 Gy).
The other one already had a brachytherapy with 3 × 8 Gy
and received another 40 Gy EBRT after resection and
IOERT (IOERT dose: 15 Gy).
Overall Survival (OS), Local Progression-free Survival
(LPFS) and Distant Progression-free Survival (DPFS)
were evaluated. Statistical events were defined as death
from any cause (OS), any loco-regional relapse (LPFS)
and occurrence of any distant metastases or positive
lavage cytology (DPFS). Time to event data was mea-
sured from the date of resection and IOERT and ana-
lyzed using the Kaplan-Meier method. Subgroups were
compared with the log-rank-test, categorical variables
with the chi-square-method, using SPSS version 20. A
p value of < 0.05 was considered statistically significant.
Results
Patient characteristics
18 patients with recurrent cervical cancer (5 with adeno-
carcinoma and 13 with squamous cell carcinoma), 12
patients with recurrent endometrial, and 6 patients with
recurrent vulvar cancer were identified. Patients had a
median follow-up of 14 months (range: 0.1–154 months).
The demographic and clinicopathological characteristics
are summarized in Table 2. Median age at date of resec-
tion and IOERT was 53.5 years. The median time to re-
currence from the date of first diagnosis was 55.9 months
(range: 7–227 months). 20 of the 36 patients (55.6 %) had
an extensive tumor recurrence with infiltration of either
bladder and/or rectum, 13 patients (36.1 %) showed posi-
tive lymph nodes and 7 patients (19.4 %) a lymphangiosis
carcinomatosa. The extent of resection was depending on
the pattern of tumor recurrence, ranging from excision to
pelvic exenteration including vessel resection. Gross
complete resection had been attempted in all patients. In
15 cases R0-resection could be achieved (41.7 %), 14
patients had R1-resection (38.9 %), and only 1 patient
R2-resection (2.8 %). 6 patients had complete gross
but microscopically unclear resection margins (Rx).
Survival data
Death was documented in 25 patients - 15 with cervical,
5 with endometrial, and another 5 with vulvar cancer.
Median OS was 14 months (range 0.1–153.5 months;
24.5 months for endometrial, 10.3 months for cervical,
16 months for vulvar cancer) (Table 3).
For the entire cohort 1-year, 2-year and 5-year OS was
65.3, 36.2 and 21.7 %, respectively (Fig. 1, Table 4). For
patients with endometrial carcinoma 1-year, 2-year and
5-year OS was 83.3, 62.5, and 50 %. For patients with
cervical cancer 1-, 2-, and 5-year OS was 44.5, 25.4, and
6.4 %, and for patients with vulvar cancer 83.3, 16.7 and
16.7 %, respectively (Table 4).
Patients with endometrial carcinoma showed a signifi-
cant better OS (p = 0.038, log rank) (Fig. 2).
Local pelvic progression was documented in 18
patients - 10 with cervical, 4 with endometrial and an-
other 4 with vulvar cancer. Median time to local pro-
gression was 6 months (range 2–153.5 months;
13.1 months for endometrial, 4.7 months for cervical,
7 months for vulvar cancer) (Table 3).
Table 2 Demographic and clinicopathologic characteristics
Number Mean Median Range/
Percent
Age at initial diagnosis 50.4 49 27–76
Age at time of resection + IOERT 54.6 53.5 27–83
Time to recurrence (months) 25 55.9 7–227
Primary tumor site
Cervix 18 50 %
Endometrium 12 33.3 %
Vulva 6 16.7 %
Histology
Squamous cell carcinoma 19 52.8 %
Adenocarcinoma 13 36.1 %
Serous 3 8.3 %




Positive lymph nodes 13 36.1 %
Lymphangiosis carcinomatosa 7 19.4 %
Resection margins
R0 15 41.7 %
R1 14 38.9 %
R2 1 2.8 %
Rx 6 16.7 %
Applied dose (Gray) at IOERT 13.8 15 10–18
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1-year LPFS was 44.1 % (76.2 % for endometrial,
17.2 % for cervical, 40 % for vulvar cancer), 28 % at
2 years (61 % for endometrial, 0 % for cervical, 20 % for
vulvar cancer) and 21 % at 5 years (40.6 % for endomet-
rial, 0 % for cervical, 20 % for vulvar cancer) (Fig. 1,
Table 4). Patients with endometrial cancer showed a sig-
nificant (p = 0.017) and older patients a trend (p = 0.059)
for a better LPFS (Fig. 2).
16 patients developed distant metastases during
follow-up - 10 with cervical, 3 with endometrial and vul-
var carcinoma, respectively. Median time to distant pro-
gression was 4.6 months (range 0–153.5 months;
11.3 months for endometrial, 3.6 months for cervical
and 8.4 months for vulvar cancer) (Table 3). 1-year
DPFS was 53.1 % (74.1 % for endometrial, 36.7 % for
cervical, 60 % for vulvar cancer), 46.5 % at 2 years
(74.1 % for endometrial, 36.7 % for cervical, 30 % for
vulvar cancer) and 38.7 % at 5 years (74.1 % for endo-
metrial, 0 % for cervical, 30 % for vulvar cancer) (Fig. 1,
Table 4). There was a significant better DPFS for older
patients (p = 0.015) and a trend for a better DPFS for pa-
tients with endometrial carcinoma (p = 0.075) (Fig. 2). 12
of the 16 patients with distant metastases also had loco-
regional recurrence. Statistical analysis showed no sig-
nificance for LPFS as positive predictive factor for DPFS
or the other way around.
Further statistical analysis of possible predictive factors
was performed. Histology, time to recurrence, lympho-
nodal status, existence of lymphangiosis carcinomatosa,
organ infiltration, resection margins, and IOERT dose
were assessed. None of the mentioned parameters
showed a statistically significant influence on OS, LPFS
or DPFS (see Figure S1 in Additional file 1). Further-
more, statistical analysis using the chi square method
showed that no two parameters were statistically signifi-
cant dependent on each other, also not the two parame-
ters tumor type and age.
A subgroup analysis of all patients with recurrent cer-
vical cancer didn’t show a significant influence of tumor
histology on OS (p = 0.348), LPFS (p = 0.465) or DPFS
(p = 0.688).
Complications/Toxicity
All in all, 50 %/61 %/67 % of patients with recurrent
endometrial/cervical/vulvar cancer developed complica-
tions. 3 patients (8.3 %) died because of postoperative
complications with hemorrhagic shock (1 patient with cer-
vical, endometrial, and vulvar carcinoma, respectively). 3
patients (8.3 %) developed problems with the femoral
head. IOERT dose was usually restricted to 10–12 Gy if
major nerves had to be included in the radiation field.
Nevertheless, nerval affections occurred in 4 patients
(11.1 %) including paresis of nerves of the plexus lumbo-
sacralis, the sciatic and femoral nerve, paresthesia, incon-
tinence and pain. In one case sacral nerve roots were in
the radiation field, so that the dose was restricted to 12 Gy
Table 3 Survival outcomes by tumor type
Number Percent Median time (months)
Loco-regional recurrence 18 50 % 6
Cervical cancer 10 55.6 % 4.7
Endometrial cancer 4 33.3 % 13.1
Vulvar cancer 4 66.7 % 7
Distant metastases 16 44 % 4.6
Cervical cancer 10 55.6 % 3.6
Endometrial cancer 3 25 % 11.3
Vulvar cancer 3 50 % 8.4
Death 25 64 % 14
Cervical cancer 15 83.3 % 10.3
Endometrial cancer 5 41.7 % 24.5
Vulvar cancer 5 83.3 % 16
Fig. 1 Kaplan-Meier curves of OS (a), LPFS (b) and DPFS (c) of the whole group
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(patient already received 20 Gy brachytherapy before). In
another case the sciatic nerve had to be prepared to resect
the tumor, which was later blocked by lead sheets during
IOERT, so that a dose of 15 Gy could be administered to
the left iliac axis (prior EBRT with 45 Gy). The third
patient already had EBRT two times before (50 Gy and
39.6 Gy + 28 Gy brachytherapy boost) and developed a
paralysis of the adductor muscles after resection + IOERT
to the symphysis with 15 Gy. The fourth patient had a
tumor infiltration of the whole right pelvic side wall
including the iliac vessels, so that IOERT dose was re-
stricted to 12 Gy. Postoperative healing disorders and in-
fections occurred in 22.2 % with 5 patients suffering from
necrosis or wound dehiscence and 3 patients suffering
from abscesses/fluid retention. For 3 patients (8.3 %) a
lymphedema or lymphocele was documented. 2 patients
(5.6 %) developed a thrombosis.
Discussion
In this study, patients with recurrent cervical carcinoma
had a 1-year OS of 44.5 % with only 6.4 % alive after
5 years. Local control rates were even worse with 0 %
LPFS after 2 years. Data from Qiu et al. of 121 patients
with recurrent Stage I-II cervical cancer who received
primary radical hysterectomy showed a 5-year survival
of 22.3 % [13]. The site of relapse was a significant
Table 4 Survival outcomes based on the Kaplan-Meier method
Whole group Endometrial cancer Cervical cancer Vulvar cancer
1 year 2 year 5 year 1 year 2 year 5 year 1 year 2 year 5 year 1 year 2 year 5 year
OS 65.3 % 36.2 % 21.7 % 83.3 % 62.5 % 50 % 44.5 % 25.4 % 6.4 % 83.3 % 16.7 % 16.7 %
LPFS 44.1 % 28 % 21 % 76.2 % 61 % 40.6 % 17.2 % 0 % 0 % 40 % 20 % 20 %
DPFS 53.1 % 46.5 % 38.7 % 74.1 % 74.1 % 74.1 % 36.7 % 36.7 % 0 % 60 % 30 % 30 %
Fig. 2 Kaplan-Meier curves of OS, LPFS and DPFS by tumortype (a) and age (b)
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prognostic factor. Patients with vaginal recurrence had a
significantly better 5-year overall survival with 57.3 %,
whereas patients with recurrence at pelvis or distant
sites had a 5-year survival of 41.8 and 10.9 %, respect-
ively [13]. The different survival outcomes compared to
the present study may be explained by the different pa-
tient collectives. In our cohort we had many patients
with advanced stage cervical cancer who already had
many prior therapies including radical hysterectomy,
radiotherapy, radiochemotherapy or often a combination
of several modalities, so that the collective was a priori a
negatively selected one. Furthermore, salvage treatment
in the cohort of Qiu et al. consisted of different treat-
ment modalities including surgery, radiotherapy, chemo-
therapy or a combination of these, whereas our patients
all received a resection combined with IOERT.
If resection or radiation of recurrent cervical cancer is
not possible, palliative platin-based chemotherapy has
been the only treatment option until recently. Mean
Overall Survival rates ranging from 6.5 to 18.3 months
have been reported with mean Progression-free Survival
rates of 2.8 to 6.9 months [27–30]. The tumor response
to chemotherapy depends on many factors. Black
race, performance status > 0, pelvic disease, previous
radiosensitizer and time interval from diagnosis to
first recurrence < 1 year have been identified as risk
factors for poor response [31]. In our cohort, 10 pa-
tients with cervical cancer already had prior chemo-
therapy treatment and all patients had pelvic disease
so that a good response of the tumor to chemother-
apy would have been unlikely. With 5-year survival
rates of 6.4 % after resection and IOERT and even
poor local control rates in our cohort, this treatment
should also be considered a rather palliative one. It is
a very individual decision in which case of recurrent
cervical carcinoma an extensive resection combined
with IOERT is reasonable and ethically acceptable.
Treatment for patients with loco-regional recurrence
of endometrial cancer in a previously irradiated field is
discussed controversially. Surgical resection with or
without IOERT is one curative treatment option. 5-year
survival rates of 40–45 % after pelvic exenteration have
been reported [32, 33]. There are limited data on the use
of IOERT for recurrent endometrial cancer. Chemother-
apy has also been shown to have activity in endometrial
cancer. Median PFS of 8.3 months and median OS of
15.3 months have been demonstrated by the GOG 177
protocol using paclitaxel, doxorubicin and cisplatin, but
with a high incidence of peripheral neuropathy (12 %)
[34]. In our cohort, patients with recurrent endometrial
carcinoma showed a median survival of 24.4 months
and a 5-year Overall Survival of 50 % with 5-year loco-
regional and distant control rates of 40.6 and 74.1 %,
respectively. In general, patients’ age seemed to be a
prognostic parameter, as older patients had a better local
and distant progression-free survival. This might be due
to the fact that endometrial carcinoma is generally asso-
ciated with older age. However, statistical analysis using
the chi-square-method didn’t show any statistically sig-
nificant dependence of tumor type and age, as the pa-
tients’ collective was too small.
A recent study suggested that in recurrent endometrial
carcinoma residual disease is the most important prog-
nostic factor after resection for both Progression-free
Survival and Overall Survival [35]. Estimated 5-year
PFS/OS was 42 %/60 % in optimally and 19 %/30 % in
suboptimally cytoreduced patients [35]. Furthermore, lit-
erature suggests that patients with complete gross resec-
tion of gynecologic recurrences also have the greatest
benefit from IOERT [1, 36, 37]. The survival outcomes
in our group were similar to those of the optimally
cytoreduced patients in the cohort of Papadia et al. In
the present study the resection status seemed to have no
influence on outcome as already shown in other studies
evaluating the effect of IOERT [38]. Patients with free
resection margins (R0) didn’t show a better OS, LPFS or
DPFS than those with microscopically positive (R1) or
complete gross but microscopically unclear (Rx) resec-
tion margins. There was only one patient with gross re-
sidual disease (R2) so that further statistical analysis of
the resection status is not reasonable. Also positive lym-
phonodal status or lymphangiosis carcinomatosa had no
significant influence on the outcome in contrast to other
studies [12, 39–41]. These findings may be explained by
compensating effects of IOERT.
The cohort of patients with vulvar carcinoma was very
small, so that it’s hard to make any statistical prediction,
especially in a retrospective setting. In general, because
of the rarity of recurrent vulvar cancer, only few clinical
trials have been performed and the level of evidence for
different treatment modalities is poor. In our cohort,
survival seemed to be a little better compared to patients
with recurrent cervical carcinoma, but not as good as
survival of patients with recurrent endometrial carcin-
oma with a 5-year OS, LPFS and DPFS of 16.7, 20 and
30 %, respectively.
Treatment of recurrent gynecologic cancer remains a
challenging issue. In general, pelvic exenteration can be
considered in cases of recurrent or advanced-stage
tumors with bladder and/or rectum infiltration neither
extended to the pelvic side walls nor showing any distant
metastases. With the possibility to use IOERT even
patients with a recurrence of the pelvic side wall have a
chance for good local control. But complications are
likely, both of pelvic exenteration and IOERT, which
have to be considered. The overall morbidity of pelvic
exenteration is described in literature with about 70 %
[12, 22, 23]. Apart from common early surgical
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complications such as large volume blood loss, sepsis or
thromboembolic accidents, there may occur problems
related to the denuded pelvic wall and floor like ab-
scesses, intestinal fistulas and bowel obstructions. But
there are also many long-term toxicities that must be
taken into consideration, such as chronic and recurrent
urinary infections, obstruction, pyelonephritis, renal in-
sufficiency, loss of sexual function, pouch stones, etc.
[12]. Most common complications of IOERT are periph-
eral nervous injury (18–30 %), gastrointestinal toxicity
(15–24 %), and ureteral obstructions (3 %) [36, 42]. In
our collective the postoperative mortality was higher
than described in the literature with 8.3 % of patients
dying from hemorrhagic shock. This might be due to the
extent of resection including vessel reconstruction, prior
radiotherapy, or even IOERT. The incidence of compli-
cations caused by IOERT described in literature [36, 42]
is quite high. With the use of modern techniques as de-
scribed above complications can be reduced. In general,
it is hard to distinguish between complications caused
by resection and those caused by IOERT retrospectively.
3 patients developed problems with the femoral head, in
only one case an osteoradionecrosis could definitely be
diagnosed, which was probably caused by prior pelvic
EBRT. Most complications were healing disorders, lymph-
atic disorders and nerval affections that could be caused
by both radiation treatment and/or resection. One of the
patients with thrombosis had a vascular interponate.
All in all, patients with recurrent endometrial cancer
seem to have the greatest benefit from resection com-
bined with IOERT with 5-year survival rates of 50 %. In
these patients, resection combined with IOERT can be
regarded as valid curative treatment option and should
be discussed with the patient. Patients with cervical or
vulvar cancer have a much worse survival. With 5-year
survival rates of 6.4 and 16.7 %, respectively, and even
poor local control rates, this treatment should be con-
sidered a rather palliative one.
It is a very individual decision in which case of recurrent
cervical carcinoma an extensive resection combined with
IOERT is reasonable and ethically acceptable, especially in
regard to the above-mentioned side effects. Patients should
be selected carefully to define those who may benefit from
that aggressive kind of treatment. Today there are much
better diagnostic options considering technical develop-
ment of MRI or PET-CT to identify patients with limited
local recurrences eligible for resection and IOERT. The
risk of distant progression in this patient collective should
not be underestimated. In our collective, 55.6 % of all
patients with recurrent cervical carcinoma developed dis-
tant metastases. In these cases or if the patient’s perform-
ance status isn’t good enough and the expected morbidity
is high, other therapy options should be considered as well.
Literature suggests that new targeted therapies show
satisfactory results in advanced stages of recurrent cervical
cancer. Tewari et al. showed that bevacizumab combined
with chemotherapy resulted in a median survival of
17 months compared to 13.3 months with chemotherapy
alone in the GOG 40 trial [43]. Toxicities were adequate
and life quality not significantly affected by this therapy. In
any case the radical surgical approach should be weighted
carefully against other less invasive therapy options like the
bevacizumab regime. For some patients even a combin-
ation of both modalities might be considered. On the other
hand, advances in highly conformal radiotherapy tech-
niques might offer new treatment options in combin-
ation with systemic approaches, thus avoiding extensive
surgical approaches.
Conclusion
The radical procedure of resection combined with
IOERT seems to be a valid curative treatment option for
patients with recurrent endometrial carcinoma with 5-
year survival rates of 50 %. For patients with cervical or
vulvar cancer this treatment should be considered a ra-
ther palliative one. Radical surgery should be weighted
carefully against other treatment options like chemo-
therapy, targeted therapies or new highly conformal
radiotherapy techniques.
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Additional file 1: Figure S1. Kaplan-Meier curves of OS [A], LPFS [B]
and DPFS [C] by different clinical parameters like histology, time to
recurrence, lymphonodal status, lymphangiosis carcinomatosa,
organinfiltration, resection status, and applied dose of IOERT. Further
statistical analysis of possible predictive factors was performed. Histology,
time to recurrence, lymphonodal status, lymphangiosis carcinomatosa,
organinfiltration, resection status, and applied dose of IOERT were
assessed. None of the mentioned parameters showed a statistically
significant influence on OS, LPFS or DPFS. (PDF 357 kb)
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